Remogliflozin Etabonate: First Global Approval
This article summarizes the milestones in the development of remogliflozin etabonate leading to this first approval for T2DM. (Source: Drugs)
Source: Drugs - June 14, 2019 Category: Drugs & Pharmacology Source Type: research

Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis
AbstractGlucocorticoids (GCs) are often used for improvement of quality of life, particularly in the elderly, but long-term GC use may cause harm; bone loss and fractures are among the most devastating side effects. Fracture risk is particularly high in patients with a severe underlying disease with an urgent need for treatment with high-dose GCs. Moreover, it is important to realize that these patients suffer from an augmented background fracture risk as these patients have a high presence of traditional risk factors for osteoporosis, such as high age, low body mass index (BMI), smoking and relatives with osteoporosis or ...
Source: Drugs - June 14, 2019 Category: Drugs & Pharmacology Source Type: research

Artificial Pancreas: Current Progress and Future Outlook in the Treatment of Type 1 Diabetes
AbstractType 1 diabetes is characterised by insulin deficiency caused by autoimmune destruction of the pancreatic beta cells. The treatment of type 1 diabetes is exogenous insulin in the form of multiple daily injections or continuous subcutaneous insulin infusion. Advances in diabetes technology have been exponential in the past few decades, culminating in studies to develop an automated artificial pancreas, also known as the closed-loop system. This has recently led to a commercially available, hybrid artificial pancreas in the USA and Europe. This review article aims to provide an overview of the rationale for an artifi...
Source: Drugs - June 12, 2019 Category: Drugs & Pharmacology Source Type: research

A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy
AbstractThe inflammatory bowel diseases commonly affect individuals during their peak reproductive years. Patients are often concerned about the impact of medical therapies on their ability to conceive, effect on the fetus, as well as the ability to breastfeed, which has led to poor medical adherence during pregnancy. However, most medications are safe, and discontinuation may lead to active disease, which is associated with adverse materno-fetal outcomes. The anti-TNF biologic therapies, infliximab and adalimumab have been extensively studied in the context of pregnancy. They are actively transferred to the placenta durin...
Source: Drugs - June 10, 2019 Category: Drugs & Pharmacology Source Type: research

Sotagliflozin: First Global Approval
This article summarizes the milestones in the development of sotagliflozin leading to this first approval in the EU as an adjunct to insulin in patients with T1DM with a body mass index ≥ 27 kg/m2 who have failed to achieve adequate glycaemic control despite optimal insulin therapy. (Source: Drugs)
Source: Drugs - June 6, 2019 Category: Drugs & Pharmacology Source Type: research

Erdafitinib: First Global Approval
This article summarizes the milestones in the development of erdafitinib leading to this first approval for the treatment of urothelial carcinoma. (Source: Drugs)
Source: Drugs - June 3, 2019 Category: Drugs & Pharmacology Source Type: research

Recent Developments in LRRK2-Targeted Therapy for Parkinson ’s Disease
AbstractKinase activating missense mutations in leucine-rich repeat kinase 2 (LRRK2) are pathogenically linked to neurodegenerative Parkinson ’s disease (PD). Over the past decade, substantial effort has been devoted to the development of potent and selective small molecule inhibitors of LRRK2, as well as their preclinical testing across different Parkinson’s disease models. This review outlines the genetic and biochemical evidence th at pathogenic missense mutations increase LRRK2 kinase activity, which in turn provides the rationale for the development of small molecule inhibitors as potential PD therapeutics...
Source: Drugs - June 3, 2019 Category: Drugs & Pharmacology Source Type: research

Siponimod: First Global Approval
This article summarizes the milestone in the development of siponimod leading to this first global approval for MS in the USA. (Source: Drugs)
Source: Drugs - May 29, 2019 Category: Drugs & Pharmacology Source Type: research

Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment
AbstractGlaucoma, a group of progressive optic neuropathies with similar patterns of tissue loss, is primarily treated with medical therapy, followed by laser therapy and, later, incisional surgery. Aside from the introduction of prostaglandin analogs, topical carbonic anhydrase inhibitors, and topical alpha-agonists in the 1990s, no new pharmaceutical agents to lower intraocular pressure (IOP) have been introduced for approximately 20  years. The Rho kinase inhibitors represent a new class of glaucoma medications that inhibit the downstream pathway of the Rho family of small G-proteins to increase outflow from the co...
Source: Drugs - May 27, 2019 Category: Drugs & Pharmacology Source Type: research

Mechanism of Action and Clinical Attributes of Auryxia ® (Ferric Citrate)
AbstractChronic kidney disease (CKD) is a major cause of morbidity and premature mortality and represents a significant global public health issue. Underlying this burden are the many complications of CKD, including mineral and bone disorders, anemia, and accelerated cardiovascular disease. Hyperphosphatemia and elevated levels of fibroblast growth factor 23 (FGF23) have been identified as key independent risk factors for the adverse cardiovascular outcomes that frequently occur in patients with CKD. Auryxia® (ferric citrate; Keryx Biopharmaceuticals, Inc., Boston, MA, USA) is an iron-based compound with distinctive ch...
Source: Drugs - May 27, 2019 Category: Drugs & Pharmacology Source Type: research

Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain
AbstractIncreases in cancer diagnosis have tremendous negative impacts on patients and their families, and major societal and economic costs. The beneficial effect of chemotherapeutic agents on tumor suppression comes with major unwanted side effects such as weight and hair loss, nausea and vomiting, and neuropathic pain. Chemotherapy-induced peripheral neuropathy (CIPN), which can include both painful and non-painful symptoms, can persist 6  months or longer after the patient’s last chemotherapeutic treatment. These peripheral sensory and motor deficits are poorly treated by our current analgesics with limited ...
Source: Drugs - May 24, 2019 Category: Drugs & Pharmacology Source Type: research

Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities
AbstractFibrosis is a common outcome of most chronic inflammatory diseases, characterized by the accumulation of excessive extracellular matrix components. Individuals with progressive liver fibrosis develop cirrhosis, are at risk of developing liver cancer, and may succumb to liver failure. Although a number of specific therapies for different diseases have been developed and successfully used, for example, direct antiviral agents in treatment for hepatitis C, effective and specific antifibrotic therapies are still not available. Liver biopsy remains the gold standard of staging liver fibrosis. However, transient elastogr...
Source: Drugs - May 22, 2019 Category: Drugs & Pharmacology Source Type: research

Tiotropium/Olodaterol: A Review in COPD
AbstractTiotropium/olodaterol (Stiolto® Respimat®; Spiolto® Respimat®) is an inhaled fixed-dose combination of the long-acting muscarinic antagonist tiotropium bromide (hereafter referred to as tiotropium) and the long-acting β2-adrenergic agonist olodaterol. It is available in several countries, including the USA, Japan, China and those of the EU, where it is indicated for the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The efficacy of tiotropium/olodaterol 5/5  μg/day in patients with COPD was evaluated in phase III or IV trials of 6&nda...
Source: Drugs - May 22, 2019 Category: Drugs & Pharmacology Source Type: research

Nutritional Psychiatry: From Concept to the Clinic
AbstractThe field of ‘nutritional psychiatry’ has evolved with rapidity over the past several years, with an increasing amount of dietary or nutrient-based (nutraceutical) intervention studies being initiated, and more preclinical and epidemiological data being available. This emergent paradigm involves the clinical consideration (where appropriate) of prescriptive dietary modification/improvement, and/or the select judicious use of nutrient-based supplementation to prevent or manage psychiatric disorders. In the last several years, significant links have increasingly been established between dietary quality a ...
Source: Drugs - May 21, 2019 Category: Drugs & Pharmacology Source Type: research

Medical Management of Cushing ’s Syndrome: Current and Emerging Treatments
AbstractEndogenous Cushing ’s syndrome is a chronic disease associated with increased morbidity and mortality if not appropriately treated. Recurrence and/or persistence of hypercortisolemia after surgical treatment, especially for Cushing’s disease, are high, and long-term medical treatment is used to decrease cortisol l evels and risk of metabolic comorbidities. Medical treatment is also often required while waiting for radiation effects to take place. In some cases, severe or life-threatening hypercortisolism must be urgently and medically treated, via intravenous medications or with combination therapy, bef...
Source: Drugs - May 17, 2019 Category: Drugs & Pharmacology Source Type: research

Risankizumab: First Global Approval
This article summarizes the milestones in the development of risankizumab leading to this first approval for psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis. (Source: Drugs)
Source: Drugs - May 17, 2019 Category: Drugs & Pharmacology Source Type: research

Correction to: Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
The original article has been corrected. (Source: Drugs)
Source: Drugs - May 17, 2019 Category: Drugs & Pharmacology Source Type: research

Teriflunomide: A Review in Relapsing –Remitting Multiple Sclerosis
AbstractTeriflunomide (Aubagio®) is a disease-modifying immunomodulatory drug with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydro-orotate dehydrogenase, with consequent inhibition of de novo pyrimidine synthesis and reduced lymphocyte proliferation. Based on extensive evidence from randomized controlled trials (RCTs) and the real-world setting, oral teriflunomide is an effective and generally well tolerated treatment in patients with relapsing multiple sclerosis (MS), with these benefits maintained during long-term treatment ( ≥ 10 years) and no new...
Source: Drugs - May 16, 2019 Category: Drugs & Pharmacology Source Type: research

Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy
AbstractTransthyretin amyloidosis with polyneuropathy (ATTR-PN), a rare and progressive hereditary disorder, results from mutations in the gene coding for the transthyretin (TTR) protein that destabilize the protein ’s tetrameric structure. In over 40 countries worldwide, tafamidis (Vyndaqel®) is approved for the treatment of TTR amyloidosis in adults with stage 1 symptomatic polyneuropathy, to delay peripheral neurological impairment. Tafamidis is administered orally once daily, as a soft capsule. Evidence from clinical studies, including an 18-month placebo-controlled trial and subsequent long-term, open-label ...
Source: Drugs - May 16, 2019 Category: Drugs & Pharmacology Source Type: research

Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents
AbstractAzole antifungals are first-line options in the prophylaxis and treatment of invasive fungal infections. They are often used for prolonged (weeks to months) periods of time, particularly in patients with hematologic malignancies, or in those who have received a solid organ or hematopoietic stem cell transplant. Long-term use of azoles is associated with hepatotoxicity and hormone-related effects, including gynecomastia, alopecia, decreased libido, oligospermia, azoospermia, impotence, hypokalemia, hyponatremia, and (rarely) adrenal insufficiency. Voriconazole and posaconazole have been associated with peripheral ne...
Source: Drugs - May 15, 2019 Category: Drugs & Pharmacology Source Type: research

Peficitinib: First Global Approval
This article summarizes the milestones in the development of peficitinib leading to this first approval as a treatment for rheumatoid arthritis in patients who have an inadequate response to conventional therapies. (Source: Drugs)
Source: Drugs - May 15, 2019 Category: Drugs & Pharmacology Source Type: research

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer
AbstractThe use of targeted therapy in the management of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer is an important milestone in the management of advanced lung cancer. There are several generations of EGFR tyrosine kinase inhibitors available for clinical use. Dacomitinib is a second-generation irreversible EGFR tyrosine kinase inhibitor with early-phase clinical studies showing efficacy in non-small-cell lung cancer. In the recently published ARCHER 1050 phase III study, dacomitinib given at 45  mg/day orally was superior to gefitinib, a first-generation reversible EGFR tyrosine kinas...
Source: Drugs - May 8, 2019 Category: Drugs & Pharmacology Source Type: research

Solriamfetol: First Global Approval
This article summarizes the milestones in the development of solriamfetol leading to this first approval as a treatment for excessive daytime sleepi ness associated with narcolepsy and OSA. (Source: Drugs)
Source: Drugs - May 6, 2019 Category: Drugs & Pharmacology Source Type: research

Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?
AbstractBackgroundHyperphosphatemia control is a major issue in hemodialysis patients. Both sevelamer and nicotinamide are prescribed for this purpose. In addition, they exert pleiotropic effects such as an improvement of inflammatory status and potentially enhanced clearance of uremic toxins. In the present secondary analysis of the NICOREN trial, we investigated the impact of sevelamer and nicotinamide on uremic toxins, toxin precursors, and endotoxemia in chronic hemodialysis patients.MethodsCirculating uremic toxins (including phenylacetylglutamine, trimethylamine-N-oxide, p-cresyl sulfate, indoxyl sulfate, kynurenine,...
Source: Drugs - May 6, 2019 Category: Drugs & Pharmacology Source Type: research

Correction to: Sarecycline: First Global Approval
The article Sarecycline: First Global Approval, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 79, issue 3, pages 325 –329 Almirall, LLC., requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Almirall, LLC. (Source: Drugs)
Source: Drugs - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
AbstractPegaspargase (Oncaspar®), a pegylated form of nativeEscherichia coli-derivedl-asparaginase (hereafter referred asE. colil-asparaginase), is indicated in the USA and EU for the treatment of acute lymphoblastic leukaemia (ALL) as a component of multi-agent chemotherapy in paediatric and adult patients. Relative toE. colil-asparaginase, pegaspargase has a prolonged circulation time, thereby offering less frequent administration. Moreover, pegylation ofE. colil-asparaginase may diminish the immunogenicity of the enzyme. Based on extensive evidence, intramuscular (IM) or intravenous (IV) administration of pegasparga...
Source: Drugs - April 27, 2019 Category: Drugs & Pharmacology Source Type: research

Brexanolone: First Global Approval
This article summarizes the milestones in the development of brexanolone leading to its first approval for the treatment of adult women with PPD. (Source: Drugs)
Source: Drugs - April 20, 2019 Category: Drugs & Pharmacology Source Type: research

Drugs in Development for Acute Kidney Injury
AbstractThe care of patients with acute kidney injury (AKI) has been limited due to the lack of effective therapeutics that can either prevent AKI during high-risk situations or treat AKI once established. A revolution in the scientific understanding of the pathogenesis of AKI has led to the identification of potential therapeutic targets. These targets include pathways involved in inflammation, cellular repair and fibrosis, cellular metabolism and mitochondrial function, oxidative stress, apoptosis, and hemodynamics and oxygen delivery. Many compounds are entering early-phase clinical trials. In addition, efforts to bette...
Source: Drugs - April 19, 2019 Category: Drugs & Pharmacology Source Type: research

Lenvatinib: A Review in Hepatocellular Carcinoma
AbstractLenvatinib (Lenvima®) is an oral small molecule inhibitor of multiple receptor tyrosine kinases, and is approved for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) in the USA, EU, Japan and China. The approval of lenvatinib was based on results of the randomized, open-label, multinational, non-inferiority phase III REFLECT trial in patients with unresectable HCC, who had not received treatment for advanced disease. In REFLECT, lenvatinib was non-inferior, but not superior, to sorafenib (current standard of care) for overall survival (OS). However, lenvatinib was associated...
Source: Drugs - April 16, 2019 Category: Drugs & Pharmacology Source Type: research

Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
AbstractAimOur aim was to assess the efficacy and safety of mipomersen through a systematic review of the literature and a meta-analysis of the available clinical studies.MethodsA systematic literature search in SCOPUS, PubMed Medline, ISI Web of Science and Google Scholar databases was conducted up to January 20, 2019, in order to identify clinical trials assessing the effect of mipomersen on lipoproteins, and the safety profile of mipomersen. Effect sizes for lipid changes were expressed as weighted mean differences (WMD) and 95% confidence intervals (CI). For safety analysis, odd ratios (OR) and 95% CI were calculated u...
Source: Drugs - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice
AbstractTeneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with at½ of approximately 24  h and unique pharmacokinetic properties: it is metabolized by cytochrome P450 (CYP) 3A4 and flavin-containing monooxygenase 3 (FMO3), or excreted from the kidney in an unchanged form. Because of its multiple elimination pathways, dose adjustment is not needed in patients with hepatic or renal impa irment, and it...
Source: Drugs - April 13, 2019 Category: Drugs & Pharmacology Source Type: research

Targeting α-Synuclein in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapeutics
AbstractParkinson ’s disease (PD), the second most common neurodegenerative movement disorder, is characterized by progressive motor and non-motor symptoms [1]. Despite treatment with pharmacologic and surgical therapies, the disease will continue to relentlessly advance. Hence, there is a great deal of interest in potential disease-modifying therapies with the hope that the neurodegenerative process can be slowed or halted. The purpose of this review is to highlight the role toxic α-synuclein (α-syn) plays in PD pathogenesis and critically review the relevant literature about therapeutic modalities targe...
Source: Drugs - April 13, 2019 Category: Drugs & Pharmacology Source Type: research

Correction to: Eravacycline: A Review in Complicated Intra-Abdominal Infections
The article Eravacycline: A Review in Complicated Intra-Abdominal Infections, written by Lesley J. Scott, was originally published Online First without open access. (Source: Drugs)
Source: Drugs - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

The Clinician ’s Guide to Proton Pump Inhibitor Related Adverse Events
AbstractA substantial volume of literature exists linking proton pump inhibitor (PPI) use with a multitude of serious adverse events. There is uncertainty, however, over whether these associations are clinically important. Excessive concern about PPI-related adverse events may leave patients at risk of harm by leaving acid-related upper gastrointestinal disease untreated. Conversely, the risk of treatments may outweigh the benefits if any of the purported adverse events are directly caused by PPI use; this is of particular concern where indications for PPI use are not present. In this paper, we review the studies which hav...
Source: Drugs - April 10, 2019 Category: Drugs & Pharmacology Source Type: research

New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship
AbstractA gradual rise in drug-resistant trends among Gram-negative organisms, especially carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR-Pseudomonas aeruginosa, and extensively-drug-resistant (XDR)Acinetobacter baumannii, poses an enormous threat to healthcare systems worldwide. In the last decade, many pharmaceutical companies have devoted enormous resources to the development of new potent antibiotics against XDR Gram-negative pathogens, particularly CRE. Some of these novel antibiotics against CRE strains are β-lactam/β-lactamase-inhibitor combination agents, while others belong to the non-β-lacta...
Source: Drugs - April 10, 2019 Category: Drugs & Pharmacology Source Type: research

Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives
AbstractThe epidermal growth factor receptor (EGFR) and RAS/RAF signaling pathway plays pivotal roles in tumor progression via proliferation, survival, invasion, and immune evasion. Two anti-EGFR monoclonal antibodies, cetuximab and panitumumab, have become essential components in the treatment of patients with metastatic colorectal cancer (mCRC). Treatment with these anti-EGFR antibodies has shown definite benefits when administered in all treatment lines and is strongly recommended as the preferred regimen to prolong survival, especially when administered in the first- and third-lines. Recent efforts have revealed not on...
Source: Drugs - April 9, 2019 Category: Drugs & Pharmacology Source Type: research

Are All Dopamine Agonists Essentially the Same?
AbstractDopamine agonists (DAs) represent an excellent treatment option for patients with Parkinson ’s disease, in both the early and advanced stages of the disease, improving motor symptoms, lowering the incidence of motor complications, and addressing several non-motor symptoms. Indeed, each of these compounds have different pharmacokinetic and pharmacodynamic properties, resulting in a unique efficacy and safety profile. Comorbidities, prominent non-motor symptoms and individual subjects’ clinical characteristics should guide the choice of a specific DA, allowing better management of the patient by optimizin...
Source: Drugs - April 9, 2019 Category: Drugs & Pharmacology Source Type: research

Drug Resistance During HIV Pre-Exposure Prophylaxis
AbstractClinical studies have demonstrated that use of tenofovir disoproxil fumarate with or without emtricitabine as antiretroviral pre-exposure prophylaxis (PrEP) can decrease the risk of human immunodeficiency virus (HIV) acquisition when medication adherence is high. However, the potential for PrEP to promote antiretroviral resistance remains an important public health consideration. We performed a search of the medical literature to identify studies that address HIV drug resistance during PrEP use. In this review, we summarize findings about emergent drug resistance during clinical trials of PrEP, case reports of sero...
Source: Drugs - April 8, 2019 Category: Drugs & Pharmacology Source Type: research

Distinct Profiles on Subjective and Objective Adherence Measures in Patients Prescribed Antidepressants
ConclusionMost patients had concordant outcomes on self-reported and objective measures of adherence. A small discordant class had high self-reported but low objective adherence. LPA will enable sensitivity analyses in future studies, for example excluding patients from the discordant class. (Source: Drugs)
Source: Drugs - April 3, 2019 Category: Drugs & Pharmacology Source Type: research

Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
The article Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease. (Source: Drugs)
Source: Drugs - April 3, 2019 Category: Drugs & Pharmacology Source Type: research

Correction to: Triamcinolone Aceonide Extended-Release: A Review in Osteoarthritis Pain of the Knee
An Online First version of this article was made available online at (Source: Drugs)
Source: Drugs - April 3, 2019 Category: Drugs & Pharmacology Source Type: research

Relugolix: First Global Approval
This article summarizes the milestones in the development of relugolix leading to this first approval for the treatment of symptoms associated with uterine fibroids. (Source: Drugs)
Source: Drugs - April 1, 2019 Category: Drugs & Pharmacology Source Type: research

Correction to: Revefenacin: First Global Approval
The article Revefenacin: First Global Approval, written by Young-A Heo, was originally published Online First without open access. After publication in volume 79, issue 1, pages 85 –91, Mylan Inc. (Canonsburg, Pennsylvania, USA) and Theravance Biopharma US, Inc. (South San Francisco, California, USA) requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Mylan Inc. (Canonsburg, Pennsylvania, USA) a nd Theravance Biopharma US, Inc. (South San Francisco, California, USA). The article is forthwith distributed under the terms of the Creative Co...
Source: Drugs - March 29, 2019 Category: Drugs & Pharmacology Source Type: research

Authors ’ Reply to Gough: “Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes”
(Source: Drugs)
Source: Drugs - March 27, 2019 Category: Drugs & Pharmacology Source Type: research

Comment on: “Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes”
(Source: Drugs)
Source: Drugs - March 27, 2019 Category: Drugs & Pharmacology Source Type: research

Contemporary Options for the Management of Motor Complications in Parkinson ’s Disease: Updated Clinical Review
AbstractParkinson ’s disease (PD) is a chronic, progressive condition affecting around 1% of the population older than 60 years. Upon long-term treatment with levodopa, the mainstay of treatment in PD, most patients, especially younger ones exposed to higher doses, will experience symptoms related to end-of-dose d eterioration, peak-dose dyskinesias, and other motor fluctuations. Therapeutic strategies are grounded on modification of oral levodopa pharmacokinetics to extend levodopa benefit and development of new routes of drug delivery (e.g., levodopa/carbidopa intestinal gel infusion) or long-acting formula ti...
Source: Drugs - March 23, 2019 Category: Drugs & Pharmacology Source Type: research

Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials
AbstractCancer accounts for 20% of all venous thromboembolism (VTE) worldwide and cancer patients are at four- to sevenfold increased risk of thrombosis compared to non-cancer patients. VTE is also a morbid complication of cancer and its incidence is rising. Thrombosis is also a second leading cause of death in cancer patients. The standard of care management for the prevention and treatment of cancer-associated thrombosis (CAT) remains the administration of low-molecular-weight heparins (LMWHs). In the last decade, five direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban, have be...
Source: Drugs - March 23, 2019 Category: Drugs & Pharmacology Source Type: research

Correction to: Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
The article Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 78, issue 17, pages 1817 –1828 Gilead Sciences requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Gilead Sciences. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International Licen se (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplica...
Source: Drugs - March 22, 2019 Category: Drugs & Pharmacology Source Type: research

Correction to: Tapentadol Prolonged Release: A Review in Pain Management
The article Tapentadol Prolonged Release: A Review in Pain Management, written by Emma D. Deeks, was originally published Online First without open access. (Source: Drugs)
Source: Drugs - March 21, 2019 Category: Drugs & Pharmacology Source Type: research

Correction to: Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee
The original article has been corrected. (Source: Drugs)
Source: Drugs - March 21, 2019 Category: Drugs & Pharmacology Source Type: research